Melanoma
Conference Coverage
One Patient Changed This Oncologist’s View of Hope. Here’s How.
“How we think about hope directly influences patient care,” according to a professor of clinical medicine at Weill Cornell Medicine in New York...
Latest News
Study Highlights Melanoma Survival Disparities in Rural vs Urban Settings
To characterize the rural population diagnosed with melanoma and assess associated disparities in the United States, researchers used data from...
Conference Coverage
Neoadjuvant Checkpoint Inhibition Study Sets New Standard of Care in Melanoma
Results of the first phase 3 oncology study to test checkpoint inhibition without chemotherapy were presented at the annual meeting of the...
News
Urine Tests Could Be ‘Enormous Step’ in Diagnosing Cancer
Cancer biomarkers in urine are not nearly as widely studied as those in the blood, but a new wave of urine tests suggests research is gaining pace...
Conference Coverage
New mRNA Vaccines in Development for Cancer and Infections
Different forms and designations of mRNA vaccines are used, depending on the application and desired effect.
News
Can a Risk Score Predict Kidney Injury After Cisplatin?
Researchers have developed a risk algorithm to predict acute kidney injury after cisplatin administration and tested it using data from six US...
News
Do Patients Benefit from Cancer Trial Participation?
Researchers conduct a meta-analysis comprising 141 comparisons of an investigational drug and a control treatment, which include immunotherapies...
News
The Long, Controversial Search for a ‘Cancer Microbiome’
Research raised as many questions as answers about what we do and don’t know about microbiota and cancer.
News
Few Cancer Survivors Meet ACS Nutrition, Exercise Guidelines
Researchers estimate more than 9,000 survivors’ adherence to weight, physical activity, fruit and vegetable consumption, and alcohol intake...
News
Most Targeted Cancer Drugs Lack Substantial Clinical Benefit
Researchers assess validity of the molecular targets and clinical benefits of genome-targeted cancer drugs approved in the United States from 2015...
